000891058 001__ 891058
000891058 005__ 20240701202016.0
000891058 0247_ $$2doi$$a10.3390/molecules26061590
000891058 0247_ $$2Handle$$a2128/27418
000891058 0247_ $$2pmid$$a33805709
000891058 0247_ $$2WOS$$aWOS:000645434200001
000891058 0247_ $$2altmetric$$aaltmetric:103579575
000891058 037__ $$aFZJ-2021-01341
000891058 082__ $$a540
000891058 1001_ $$0P:(DE-Juel1)164337$$aPost, Julia$$b0
000891058 245__ $$aA Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model
000891058 260__ $$aBasel$$bMDPI$$c2021
000891058 3367_ $$2DRIVER$$aarticle
000891058 3367_ $$2DataCite$$aOutput Types/Journal article
000891058 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719815346_15234
000891058 3367_ $$2BibTeX$$aARTICLE
000891058 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000891058 3367_ $$00$$2EndNote$$aJournal Article
000891058 520__ $$aAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterised by selective neuronal death in the brain stem and spinal cord. The cause is unknown, but an increasing amount of evidence has firmly certified that neuroinflammation plays a key role in ALS pathogenesis. Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and has been implicated as driver of disease progression. Here, we describe a treatment study demonstrating the therapeutic potential of a tandem version of the well-known all-d-peptide RD2 (RD2RD2) in a transgenic mouse model of ALS (SOD1*G93A). Mice were treated intraperitoneally for four weeks with RD2RD2 vs. placebo. SOD1*G93A mice were tested longitudinally during treatment in various behavioural and motor coordination tests. Brain and spinal cord samples were investigated immunohistochemically for gliosis and neurodegeneration. RD2RD2 treatment in SOD1*G93A mice resulted not only in a reduction of activated astrocytes and microglia in both the brain stem and lumbar spinal cord, but also in a rescue of neurons in the motor cortex. RD2RD2 treatment was able to slow progression of the disease phenotype, especially the motor deficits, to an extent that during the four weeks treatment duration, no significant progression was observed in any of the motor experiments. Based on the presented results, we conclude that RD2RD2 is a potential therapeutic candidate against ALS.
000891058 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000891058 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x1
000891058 588__ $$aDataset connected to CrossRef
000891058 7001_ $$0P:(DE-HGF)0$$aKogel, Vanessa$$b1
000891058 7001_ $$0P:(DE-Juel1)176527$$aSchaffrath, Anja$$b2
000891058 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b3
000891058 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b4
000891058 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b5
000891058 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b6
000891058 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b7
000891058 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b8$$eCorresponding author
000891058 773__ $$0PERI:(DE-600)2008644-1$$a10.3390/molecules26061590$$gVol. 26, no. 6, p. 1590 -$$n6$$p1590 -$$tMolecules$$v26$$x1420-3049$$y2021
000891058 8564_ $$uhttps://juser.fz-juelich.de/record/891058/files/Invoice_MDPI_molecules-1102502.pdf
000891058 8564_ $$uhttps://juser.fz-juelich.de/record/891058/files/molecules-26-01590.pdf$$yOpenAccess
000891058 8767_ $$8molecules-1102502$$92021-03-11$$d2021-03-15$$eAPC$$jZahlung erfolgt$$pmolecules-1102502$$zBelegnr. 1200164787 / 2021
000891058 909CO $$ooai:juser.fz-juelich.de:891058$$popenaire$$pOpenAPC$$popen_access$$pdnbdelivery$$popenCost$$pVDB$$pdriver
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164337$$aForschungszentrum Jülich$$b0$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b1$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)176527$$aForschungszentrum Jülich$$b2$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b3$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b4$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b5$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b6$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b7$$kFZJ
000891058 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b8$$kFZJ
000891058 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000891058 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x1
000891058 9130_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000891058 9141_ $$y2021
000891058 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-26
000891058 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000891058 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOLECULES : 2018$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000891058 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-26
000891058 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-26
000891058 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
000891058 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000891058 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x2
000891058 9201_ $$0I:(DE-Juel1)VDB1046$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x3
000891058 980__ $$ajournal
000891058 980__ $$aVDB
000891058 980__ $$aI:(DE-Juel1)IBI-7-20200312
000891058 980__ $$aI:(DE-Juel1)INM-4-20090406
000891058 980__ $$aI:(DE-Juel1)INM-11-20170113
000891058 980__ $$aI:(DE-Juel1)VDB1046
000891058 980__ $$aAPC
000891058 980__ $$aUNRESTRICTED
000891058 9801_ $$aAPC
000891058 9801_ $$aFullTexts